DynamiCure

Executive Summary

DynamiCure Biotechnology is a private, clinical-stage biotech company pioneering first-in-class antibody therapeutics targeting the CD93 pathway. The company’s lead program focuses on normalizing tumor vasculature and remodeling the tumor microenvironment to enhance immune infiltration and anti-tumor activity. By addressing a novel, non-redundant mechanism, DynamiCure aims to overcome resistance to existing immunotherapies and provide durable responses across multiple cancer types. Preclinical data has demonstrated robust single-agent activity and synergy with checkpoint inhibitors, positioning the platform for broad oncology utility. The company is also exploring applications in autoimmune diseases, leveraging the same immuno-normalization principles. As a private entity with minimal public disclosures, DynamiCure’s risk profile includes early-stage clinical uncertainty and reliance on future funding. The company’s asset-light model and focus on a validated target (CD93) reduce some developmental risks, but clinical proof-of-concept remains unestablished. If successful, DynamiCure could address significant unmet needs in cold tumors and autoimmune indications, representing a potential inflection point in immuno-oncology. Near-term catalysts include initial Phase 1 safety and biomarker data, which will be critical for de-risking the pipeline and attracting partnerships.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 safety and biomarker data for lead anti-CD93 antibody55% success
• Q2 2027IND filing for second oncology indication70% success
• Q1 2027Preclinical autoimmune data in lupus or IBD models60% success